Paradigm Diagnostics, a leading precision medicine company focused on comprehensive cancer testing, announced the addition of Mara Aspinall, Managing Director of BlueStone Venture Partners to the Board of Directors as part of the closing of Paradigm’s $15 million Series B fundraising. In addition to participation by the founding investors, Mesa Verde Venture Partners, New Science … Continue reading Paradigm Diagnostics Announces the Addition of Industry Executive Mara Aspinall to the Board of Directors as Part of the Series B Extension Closing Totaling $15 Million